Abstract
Tardive dyskinesia (TD) is a long-term severe complication of antipsychotic treatment, with mean prevalence of 20–35%. The aim of this study was to evaluate effects of clozapine in severe TD. In an open trial seven patients with schizophrenia and severe TD were given clozapine for 6 months. Tardive dyskinesia severity was evaluated with AIMS and ESRS and schizophrenic psychopathology with PANSS. Clozapine mean dose at the end of the study was 392.86 mg/day. A mean reduction of 52% was observed in ESRS scores for TD. Two patients also had dystonic movements, and there was 50% reduction in one of them and complete remission in the other. There was also a 27% mean reduction in PANSS scores. Clozapine seems to be an alternative in the treatment of schizophrenic patients with severe TD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received: 27 November 1997 / Accepted: 13 February 1998
Rights and permissions
About this article
Cite this article
Bassitt, D., Louzã Neto, M. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. European Archives of Psychiatry and Clinical Neurosciences 248, 209–211 (1998). https://doi.org/10.1007/s004060050039
Issue Date:
DOI: https://doi.org/10.1007/s004060050039